Yuhan Corporation, led by CEO Wook-Je Cho, disclosed on November 20th a remarkable achievement: their probiotic solution, Y's Biome DangQrak, has surged past $9.2 million in sales through online orders within just six months since its debut.

Y's Biome DangQrak stands out as a dedicated remedy designed to tackle blood sugar-related concerns affecting over 40% of the populace. It represents South Korea's sole recognized standalone probiotic endorsed by the Ministry of Food and Drug Safety (MFDS) for its ability to curtail post-meal blood sugar spikes. Since its launch in April, the product has captured substantial attention and enthusiasm, as confirmed by the company.

This breakthrough product harnesses the potential of the 'Lactobacillus HAC01' strain, a creation of AtoGEN, a company specializing in microbiome research and development. This strain not only curbs postprandial blood sugar elevation but also nurtures gut health, enhancing bowel movements and the overall intestinal microbial ecosystem. Remarkably, all this is achieved with just one capsule per day, ensuring ease and convenience.

Surpassing the $9.2 million sales milestone within six months signifies the substantial interest from diabetic and prediabetic populations. It underscores the product's credibility and the evident demand for effective blood sugar management solutions provided by Yuhan Corporation's MFDS-certified probiotic.

A Yuhan Corporation spokesperson expressed, "Our product stands as the first health functional food individually recognized by the MFDS in Korea, uniquely addressing blood sugar management as a probiotic. Its effectiveness in aiding customers requiring dietary adjustments for blood sugar management has been widely acknowledged." They further emphasized their commitment to alleviating concerns for diabetes sufferers through a product designed to ease worries.

According to the 'Diabetes Fact Sheet 2022' by the Korean Diabetes Association, South Korea had approximately 5.3 million individuals aged 30 and above grappling with diabetes in 2020, while an estimated 15 million were in the prediabetic phase. This staggering statistic underscores the imperative need for blood sugar management solutions, affecting nearly 40% of the Korean populace.